Biodesix, Inc. (NASDAQ:BDSX) CEO Sells $76,967.20 in Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at $645,791.24. This represents a 10.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Biodesix Stock Performance

Shares of BDSX opened at $0.99 on Friday. The firm has a market cap of $143.29 million, a price-to-earnings ratio of -2.53 and a beta of 1.06. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The business’s 50 day moving average is $1.23 and its two-hundred day moving average is $1.48. Biodesix, Inc. has a 52-week low of $0.86 and a 52-week high of $2.04.

Institutional Trading of Biodesix

Several institutional investors have recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. grew its holdings in Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after acquiring an additional 310,000 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in Biodesix in the third quarter worth about $262,000. Barclays PLC increased its holdings in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares during the last quarter. Geode Capital Management LLC raised its stake in Biodesix by 50.7% during the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after buying an additional 270,724 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Biodesix during the 3rd quarter worth approximately $10,849,000. 20.96% of the stock is owned by institutional investors and hedge funds.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.